Home

Wednesday, March 23, 2016

Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies.

AJT Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies.

Little is known about the impact of post-transplant blood transfusion on the sensitization of anti-HLA antibodies and the formation of donor-specific antibodies (DSAs). The aims of our study were to determine the 1-year incidence of DSAs (assessed using a solid-phase assay) and antibody-mediated rejection (AMR) in kidney-transplant patients who had or had not received a blood transfusion during the first year post-transplantation. Included were 390 non-HLA sensitized patients who had received an ABO-compatible kidney transplant, and had not previously or simultaneously received a non-kidney transplant. Sixty-four percent of patients received a red blood-cell transfusion within the first year post-transplantation, mostly within the first month. The overall 1-year incidence of DSAs was significantly higher in patients that had undergone transfusion (7.2% vs. 0.7% in patients with no transfusion, p<0.0001). AMR occurred more often in the transfusion group (n=15, 6%) compared to the non-transfusion group (n=2, 1.4%), p=0.04. Blood transfusion was an independent predictive factor for de novo DSA formation but not for AMR. Patients who had a transfusion and developed DSAs were more often treated with cyclosporin A (n=10, 55.5%) rather than tacrolimus (n=45, 19.4%), p=0.0001). In conclusion, early post-transplant blood transfusion may increase immunological risk, especially in under-immunosuppressed patients. This article is protected by copyright. All rights reserved.



http://www.unboundmedicine.com/medline/citation/26998676/Impact_of_early_blood_transfusion_after_kidney_transplantation_on_the_incidence_of_donor_specific_anti_HLA_antibodies_

Sent with Reeder



Enviado desde mi iPhone

No comments:

Post a Comment